Vimarsana
Biggest News Aggregation in the World

Page 10 - Testosterone Suppression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Testosterone Suppression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Testosterone Suppression Today - Breaking & Trending Today

Laurel Hubbard qualified fairly but should not lift at the Tokyo 2020 Olympics - Vimarsana News

Laurel Hubbard qualified fairly but should not lift at the Tokyo 2020 Olympics

The deadline for weightlifters to qualify for the delayed Tokyo 2020 Olympic Games is upon us and there is no doubt about who, among the qualifiers, wins the gold medal for attracting publicity.

High-Tech Lynching at DePaul | Frontpagemag - Vimarsana News

High-Tech Lynching at DePaul | Frontpagemag

Fri Feb 5, 2021 The Left’s thought police at DePaul University in Chicago have come after Dr. Jason D. Hill, a tenured professor of philosophy and a Shillman Journalism Fellow at the David Horowitz Freedom Center. The leftwing fascists treat every expression of views they don’t like on a controversial issue as evidence of bigotry against one or another so-called “oppressed” minority. The censors demand conformity or punishment for dissenting views. In Dr. Hill’s case, one of his former students, Grace Gallant, charged that he is "violently transphobic.” Gallant claimed...

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study) - Vimarsana News

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study) (UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer. This debate follows the publication of the HERO trial, 1  A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal ...